ישראל -
עברית -
Ministry of Health
סימבאלתה 30 מג
eli lilly israel ltd, israel - duloxetine as hydrochloride - duloxetine as hydrochloride 30 mg - duloxetine
ישראל -
עברית -
Ministry of Health
סימבאלתה 60 מג
eli lilly israel ltd, israel - duloxetine as hydrochloride - duloxetine as hydrochloride 60 mg - duloxetine
ישראל -
עברית -
Ministry of Health
דולוקס טבע 30 מג
abic marketing ltd, israel - duloxetine as hydrochloride - duloxetine as hydrochloride 30 mg - duloxetine
ישראל -
עברית -
Ministry of Health
דולוקס טבע 60 מג
abic marketing ltd, israel - duloxetine as hydrochloride - duloxetine as hydrochloride 60 mg - duloxetine
ישראל -
עברית -
Ministry of Health
דולוקסטין אס.קיי. 30 מג
k.s.kim international (sk- pharma) ltd., israel - duloxetine as hydrochloride - duloxetine as hydrochloride 30 mg - duloxetine
ישראל -
עברית -
Ministry of Health
דולוקסטין אס.קיי. 60 מג
k.s.kim international (sk- pharma) ltd., israel - duloxetine as hydrochloride - duloxetine as hydrochloride 60 mg - duloxetine
ישראל -
עברית -
Ministry of Health
דולוקסטין סנדוז 30 מג ג'י.אר.סי
novartis israel ltd - duloxetine as hydrochloride - duloxetine as hydrochloride 30 mg - duloxetine
ישראל -
עברית -
Ministry of Health
דולוקסטין סנדוז 60 מג ג'י.אר.סי
novartis israel ltd - duloxetine as hydrochloride - duloxetine as hydrochloride 60 mg - duloxetine
ישראל -
עברית -
Ministry of Health
אדקבאו 10 מגמל
novartis israel ltd - crizanlizumab - תרכיז להכנת תמיסה לאינפוזיה - crizanlizumab 10 mg/ml - crizanlizumab
ישראל -
עברית -
Ministry of Health
קומפטקט 15 מג 850 מג
tzamal bio-pharma ltd - metformin hydrochloride; pioglitazone as hydrochloride - טבליות מצופות פילם - metformin hydrochloride 850 mg; pioglitazone as hydrochloride 15 mg - metformin - metformin - competact is indicated as second line treatment of type 2 diabetes mellitus adult patients,particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.